XNASATRC
Market cap1.53bUSD
Jan 10, Last price
31.41USD
1D
-6.68%
1Q
12.82%
Jan 2017
60.50%
IPO
121.20%
Name
AtriCure Inc
Chart & Performance
Profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 399,245 20.84% | 330,379 20.43% | |||||||
Cost of revenue | 172,790 | 141,776 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 226,455 | 188,603 | |||||||
NOPBT Margin | 56.72% | 57.09% | |||||||
Operating Taxes | 591 | 268 | |||||||
Tax Rate | 0.26% | 0.14% | |||||||
NOPAT | 225,864 | 188,335 | |||||||
Net income | (30,438) -34.49% | (46,466) -192.56% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (6,557) | (6,160) | |||||||
BB yield | 0.40% | 0.30% | |||||||
Debt | |||||||||
Debt current | 2,533 | 5,472 | |||||||
Long-term debt | 83,329 | 81,318 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,234 | 1,226 | |||||||
Net debt | (51,423) | (85,832) | |||||||
Cash flow | |||||||||
Cash from operating activities | 4,484 | (22,141) | |||||||
CAPEX | (11,998) | (16,881) | |||||||
Cash from investing activities | 21,817 | 44,006 | |||||||
Cash from financing activities | (32) | (7,059) | |||||||
FCF | 205,981 | 163,001 | |||||||
Balance | |||||||||
Cash | 137,285 | 121,113 | |||||||
Long term investments | 51,509 | ||||||||
Excess cash | 117,323 | 156,103 | |||||||
Stockholders' equity | (358,002) | (330,668) | |||||||
Invested Capital | 899,898 | 863,196 | |||||||
ROIC | 25.62% | 22.11% | |||||||
ROCE | 41.79% | 35.42% | |||||||
EV | |||||||||
Common stock shares outstanding | 46,309 | 45,740 | |||||||
Price | 35.69 -19.58% | 44.38 -36.17% | |||||||
Market cap | 1,652,768 -18.58% | 2,029,941 -36.59% | |||||||
EV | 1,601,345 | 1,944,109 | |||||||
EBITDA | 241,268 | 200,313 | |||||||
EV/EBITDA | 6.64 | 9.71 | |||||||
Interest | 6,925 | 4,986 | |||||||
Interest/NOPBT | 3.06% | 2.64% |